Abstract: The invention concerns a device for injecting a solid medicine (10) comprising a body (2) inside which moves along a general forward moving axis (X-X) a bevelled (34) needle (4) wherein is introduced the medicine (10), said injection device (1) further comprising retaining means for preventing the medicine from falling (10) prior to being injected. The invention is characterized in that the medicine (10) is retained through an elastic deformation imparted to the needle (4) by the retaining means or by an elastic deformation of the retaining means themselves, or still by the combined flexibility of those two means.

Abstract: The present invention relates to peptides with anti-proliferative activity, of sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.

Abstract: The present invention relates to new derivatives of imidazo, pyrimido and diazepine-pyrimidine-dione of the general formula (I) in which R1, R2, L1, L2, Y, Z and A are various and varying groups. These products exhibit a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said products, and to the use thereof for preparing a drug.

Abstract: The invention concerns a novel method for synthesis of 1,4-morpholine-2,5-diones of formula (I), wherein: R, R1, R2, R3 and R4 independently represent various radicals, by oxidizing the ketone function of a cyclic compound of formula (II).

Abstract: A process for preparing recombinant heterocarpine with the complete sequence of heterocarpine (SEQ. ID. NO. 10), expression vectors comprising a polynucleotide encoding for heterocarpine, host cells transformed or transfected by said expression vectors as well as a process for obtaining heterocarpine by means of said transformed or transfected host cells are described where in the recombinant heterocarpine obtained is used to treat cancer.

Abstract: A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.

Abstract: The invention relates to a product comprising (1R)-1-[(({2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydrolmidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected from morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or out over the time for pain treatment or prevention.

Abstract: Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8?-ergolinglmethylthioacetyl-D-Phe-c-(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2.

Abstract: The invention relates to a device which is used to inject an implant (6) into tissues (50). The inventive device is characterized in that it comprises : a main hollow body (2; 2?) having a hollow needle (4; 4?) fixed thereto, into which the implant (6) is introduced; a secondary body (26; 26?) which is disposed coaxially inside the main body (2; 2?) and which surrounds the needle (4; 4?); and a plunger rod (36; 36?) which can slide coaxially inside the hollow needle (4; 4?).

Abstract: The present invention relates to peptides with anti-proliferative activity, of sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.

Abstract: Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo.

Abstract: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.

Abstract: The invention concerns the use or a fragment of botulinum toxin having said toxin activity for preparing a medicine for reversibly desensitizing an area of the skin, said skin area being designed to receive injections. Said injections can be related, for example, to repeated delivery of insulin, growth hormones or other medicines in injectable form.

Abstract: The invention concerns novel imidazole derivatives of general formula (I), wherein Z? and Z represent different variable groups. Said products have an antitumoral activity. The invention also concerns pharmaceutical compositions containing said products and their use for preparing antitumoral medicine.

Abstract: A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer.

Abstract: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment.

Abstract: Novel imidazole compounds of the formula wherein the substituents are as defined in the application having antitumoral activity and use thereof.

Abstract: This invention relates to a series of PTH and PTHrP analogues that selectively bind to PTH2 receptors and as such may be useful in treating abnormal CNS functions; abnormal pancreatic functions; divergence from normal mineral metabolism and homeostasis; male infertility; regulation of abnormal blood pressure; and hypothalmic disease.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

Abstract: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate or calcitonin.